Invicro was founded with the mission of improving the role of imaging in drug discovery and development across all therapeutic areas.
Invicro releases its new data management (iPACS®) and image analysis platforms (VivoQuantTM).
First 3D segmentation method launched in VivoQuantTM.
Invicro opens new headquarters and imaging facilities in Boston, MA and London, UK.
Invicro opens new translational imaging center at MPI Research in Michigan.
Invicro offers cryofluorescence tomography (CFT) as a novel 3D tissue imaging service to visualize fluorescently labeled test articles with enhanced resolution and sensitivity. Learn More
Invicro launches services to partner with pharmaceutical & commercial radiopharmaceutical producers to supply radiotracer doses for Phase I-III trials.
MNI is acquired; strengthening our full spectrum translational imaging expertise.
Imanova is acquired; opening London clinic and offices to expand our global imaging analytics and clinical services.
Invicro expands its clinical operations and opens a satellite office in Pennsylvania.
Learn More About Our Clinical Services
Invicro is acquired by Konica Minolta (KM), to support the expansion of KM's precision medicine vision through molecular digital imaging technologies, advanced analytics and software solutions.
Developed by Konica Minolta, QuanitcellTM is a novel, highly sensitive and quantitative immunohistochemistry assay that detects biomarkers in context across a broader dynamic range using phosphor-integrated dots.
KMPMJ brings together cutting-edge technologies in genomics, AI-analytics and integrated diagnostics to diagnose, treat and develop new therapies.
Invicro acquires Biocare Medical Pharma Services to provide partners access to best-in-class clinical anatomical pathology services, including IHC, IF, ISH, pathology interpretation and image analysis in a CAP-accredited, CLIA-certified laboratory.
Invicro launches it's 21 CFR Part 11 compliant TauIQ services in its Core Lab as part of its expanded IQ-Analytics Platform, which includes AmyloidIQ and DaTIQ.
AWS supports the build-out of the company’s LATTICE, a groundbreaking integrated diagnostic data platform that combines genomics, pathology, and radiology data to uncover new, clinically relevant biomarkers and create the next generation of diagnostic tests.